KPTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the mixed signals from technical indicators, options data, and financial performance, along with the lack of strong proprietary trading signals, Karyopharm Therapeutics Inc (KPTI) is not a strong buy for a beginner, long-term investor at this time. The stock may have potential upside in the future, but current uncertainties around clinical trial outcomes and analyst sentiment suggest holding off on an investment for now.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD is positive, indicating a potential upward trend. However, RSI is neutral at 56.277, and the stock is currently trading near its pivot point of 8.724, suggesting limited immediate momentum.
Karyopharm's selinexor has regulatory approvals in multiple countries and targets a significant market gap in myelofibrosis treatment. The upcoming presentation at the ASCO Annual Meeting could provide additional visibility and potential positive sentiment.
Recent mixed Phase III SENTRY trial results have introduced uncertainty regarding FDA approval for selinexor in myelofibrosis. Analysts have lowered price targets, and there is no significant insider or hedge fund activity to indicate strong confidence in the stock.
In Q4 2025, revenue increased by 11.58% YoY, and net income improved significantly by 232.03% YoY, though it remains negative at -$102.2M. EPS improved by 54.77% YoY but is still negative at -5.68. Gross margin remains strong at 95.65%.
Analysts have mixed views, with several lowering price targets recently. RBC Capital, Piper Sandler, Baird, and H.C. Wainwright have all reduced their targets, citing uncertainties around clinical trial results and approval probabilities. However, some analysts maintain Outperform or Buy ratings, reflecting potential long-term upside.
